Opportunistic Infections Caused by dsDNA Viruses Occur Early in the Post-Transplant Period and Support Need for Preventive Therapies
DURHAM, N.C., Sept. 21, 2015 (GLOBE NEWSWIRE) — Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, presented findings from a new study that show hospital readmissions related to opportunistic infections are common among patients following autologous and allogeneic hematopoietic cell transplant (HCT), also known as bone marrow or stem cell transplant. The study showed that of hospital readmissions related to opportunistic infections (25.8 percent of all readmissions), approximately 1 in 3 readmissions were due to double-stranded DNA (dsDNA) viral infections. Among dsDNA viral infections diagnosed after hospital discharge, almost half occurred within the first month after discharge. The study also showed that the majority of hospital readmissions among HCT recipients were major or extreme in severity. These data were presented during the 55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego.